<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Shiratori K</submitter><funding>Japan Society for the Promotion of Science</funding><pagination>21385-21393</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9347767</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(33)</volume><pubmed_abstract>Clusterin is a heavily glycosylated protein that is upregulated in various cancer and neurological diseases. The findings by the Hancock and Iliopoulos group that levels of the tryptic glycopeptide derived from plasma clusterin, &lt;sup>372&lt;/sup>Leu-Ala-Asn-Leu-Thr-Gln-Gly-Glu-Asp-Gln-Tyr-Tyr-Leu-Arg&lt;sup>385&lt;/sup> with a biantennary disialyl &lt;i>N&lt;/i>-glycan (A2G2S2 or FA2G2S2) at Asn374 differed significantly prior to and after curative nephrectomy for clear cell renal cell carcinoma (RCC) patients motivated us to verify the feasibility of this glycopeptide as a novel biomarker of RCC. To determine the precise &lt;i>N&lt;/i>-glycan structure attached to Asn374, whether A2G2S2 is composed of the Neu5Acα2,3Gal or/and the Neu5Acα2,6Gal moiety, we synthesized key glycopeptides having one of the two put</pubmed_abstract><journal>RSC advances</journal><pubmed_title>Selective reaction monitoring approach using structure-defined synthetic glycopeptides for validating glycopeptide biomarkers pre-determined by bottom-up glycoproteomics.</pubmed_title><pmcid>PMC9347767</pmcid><funding_grant_id>19H00918</funding_grant_id><funding_grant_id>25220206</funding_grant_id><pubmed_authors>Hirane N</pubmed_authors><pubmed_authors>Otaki M</pubmed_authors><pubmed_authors>Ohyama C</pubmed_authors><pubmed_authors>Yoneyama T</pubmed_authors><pubmed_authors>Shiratori K</pubmed_authors><pubmed_authors>Wakui H</pubmed_authors><pubmed_authors>Nishimura SI</pubmed_authors><pubmed_authors>Yokoi Y</pubmed_authors><pubmed_authors>Hinou H</pubmed_authors><pubmed_authors>Kimura S</pubmed_authors><pubmed_authors>Hatakeyama S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Selective reaction monitoring approach using structure-defined synthetic glycopeptides for validating glycopeptide biomarkers pre-determined by bottom-up glycoproteomics.</name><description>Clusterin is a heavily glycosylated protein that is upregulated in various cancer and neurological diseases. The findings by the Hancock and Iliopoulos group that levels of the tryptic glycopeptide derived from plasma clusterin, &lt;sup>372&lt;/sup>Leu-Ala-Asn-Leu-Thr-Gln-Gly-Glu-Asp-Gln-Tyr-Tyr-Leu-Arg&lt;sup>385&lt;/sup> with a biantennary disialyl &lt;i>N&lt;/i>-glycan (A2G2S2 or FA2G2S2) at Asn374 differed significantly prior to and after curative nephrectomy for clear cell renal cell carcinoma (RCC) patients motivated us to verify the feasibility of this glycopeptide as a novel biomarker of RCC. To determine the precise &lt;i>N&lt;/i>-glycan structure attached to Asn374, whether A2G2S2 is composed of the Neu5Acα2,3Gal or/and the Neu5Acα2,6Gal moiety, we synthesized key glycopeptides having one of the two put</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2026-05-09T13:39:40.116Z</modification><creation>2025-04-04T08:01:38.128Z</creation></dates><accession>S-EPMC9347767</accession><cross_references><pubmed>35975084</pubmed><doi>10.1039/d2ra02903k</doi></cross_references></HashMap>